Australian Pharmaceutical Industries Ltd
ASX: API · Health Care · Health Care Distributors
- Market cap
- A$502.4M
- P/E (trailing)
- n/m (loss)
- EPS (FY21)
- $0.00
- Dividend / share
- $0.04
- 52-week range
- –
- Intrinsic value
- –
Share price
ASX: API · AUD
Valuation
Full valuation analysis →No model currently produces a reliable estimate for API. The valuation page explains why.
Revenue
As reported · financial years
Earnings per share
Diluted · as reported
Profit margins
Gross, operating and net margin by financial year
Poor Net margin of 0.0% in FY21: barely profitable at the bottom line.
Shares outstanding
Diluted · falling means buybacks, rising means dilution
Stable -0.0% year-on-year, +0.1% a year over 10 years: share count has been stable over the long run.
Working-capital days
Days of revenue sitting in receivables (DSO) and days of cost sitting in inventory (DIO)
Steady collections DSO of 54 days vs a 61-day norm: collection times are in line with the historical norm.
Financial health
Latest financial year (FY21)
- Return on equity
- 0.3%
- Poor
- Current ratio
- 1.20
- Adequate
- Debt to equity
- 0.72
- Moderate
- Interest coverage
- 2.3×
- Thin
Verdicts are graded against what's normal for the sector (Health Care), not a one-size-fits-all bar. Hover a tile for the reasoning.
Dividends per share
Full dividend history →Per financial year, as reported in the accounts
Cash-covered payout 17.4× FY21 earnings paid out: the dividend exceeds accounting earnings but is covered by free cash flow, since non-cash charges hold reported profit below the cash the business generates.
Free cash flow
Cash from operations minus capital spending: what the DCF model projects from
Excellent 2,264% of FY21 net profit became free cash: free cash flow exceeds reported profit.
Net debt
Borrowings and leases minus cash: the line shows how many years of operating profit (EBIT) would clear it
High leverage Net debt of $275.4M is 12.1× FY21 operating profit: it would take years of operating profit to clear the net debt.
Five-year snapshot
Figures as reported in the company's filings
| Metric | FY17 | FY18 | FY19 | FY20 | FY21 |
|---|---|---|---|---|---|
| Revenue | $4.1B | $4.0B | $4.0B | $4.0B | $4.0B |
| Net profit | $52.4M | $48.2M | $56.6M | $-7.9M | $1.1M |
| EPS (diluted) | $0.11 | $0.10 | $0.11 | $-0.02 | $0.00 |
| Dividend / share | $0.07 | $0.07 | $0.08 | $0.04 | $0.04 |
| Net margin | 1.3% | 1.2% | 1.4% | -0.2% | 0.0% |
What did Australian Pharmaceutical Industries (API) do before it was delisted from the ASX?
Australian Pharmaceutical Industries, known by its ticker API, is no longer traded on the ASX, and this page serves as a historical record of the business rather than a live listing. Before delisting, the group operated as a supplier and seller of pharmaceutical items, medical supplies, and a wider range of health, beauty and lifestyle goods, channelling most of that stock into pharmacies across Australia, New Zealand and parts of Asia. Founded in 1910 and headquartered in Camberwell, Australia, the firm paired wholesale distribution with a retail arm built around pharmacy partners.
On the consumer-facing side, the company sold health and beauty products through a mix of independently franchised Priceline Pharmacy sites, its own company-run Priceline stores, and the Clear Skincare clinic network, which provided non-surgical cosmetic procedures rather than surgical ones. API had been listed on the ASX since 1997 and, based on the historical figures underlying this profile, employed 5,105 people full time, with Richard Vincent serving as chief executive.
Common questions about API
Does API pay a dividend? +–
Australian Pharmaceutical Industries Ltd paid $0.04 per share in its most recent financial year with a recorded dividend. The dividend history chart above shows the full payout record.
How fast is API growing? +–
Revenue has compounded at 0.8% a year over the last five financial years, and 1.6% a year over ten.
What is API's P/E ratio? +–
Australian Pharmaceutical Industries Ltd doesn't have a meaningful trailing P/E ratio right now. It reported a loss in FY21, and dividing a share price by negative earnings produces a figure with no useful meaning.
How did Australian Pharmaceutical Industries (API) perform financially before it delisted from the ASX?
Australian Pharmaceutical Industries Ltd (API) no longer trades on the ASX, and this page is a historical record of its reported results rather than a live listing. Across the decade of filings, revenue climbed from $3.2B in FY2012 to a peak of $4.1B in FY2017, before settling around $4.0B by FY2021. Gross margin held in a narrow band, moving between 12.1% and 13.1%, consistent with a low-margin distribution business.
Profitability was uneven. Net income of $30.3M in FY2012 gave way to a $90.8M loss in FY2014, then recovered to a decade high of $56.6M in FY2019. The final two years on record were far weaker, with a $7.9M loss in FY2020 followed by a thin $1.1M profit in FY2021. Diluted earnings per share traced the same path, falling from $0.062 in FY2012 to just $0.0023 in FY2021, having also turned negative in FY2014 (-$0.19) and FY2020 (-$0.0161).
The last recorded closing price was $1.02 on 28 September 2020. No specific fair-value outputs from valuation models were disclosed in the reported figures for this period, so no model-based comparison to that closing price can be made here.
AI-assisted analysis generated from Craytheon's verified financial data · Updated 4 Jul 2026 · How this works
Data is general information only, not financial advice. Figures are as reported in company filings (some ASX companies report in USD); share prices are AUD.